From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3βinhibitors that suppress proliferation and survival of pancreatic cancer cells

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 1853-1863

  Gaisina, Irina N ^a   Gallier, Franck ^a   Ougolkov, Andrei V ^b   Kim, Ki H ^a   Kurome, Toru ^a   Guo, Songpo ^a   Holzle, Denise ^a   Luchini, Doris N ^b   Blond, Sylvie Y ^a   Billadeau, Daniel D ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 BROMO 1 METHYL 1H INDOL 3 YL) 4 (6 HYDROXYMETHYLBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (5 BROMO 1 METHYL 1H INDOL 3 YL) 4 (6 PROP 2 YNYLOXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (5 BROMO 1 METHYL 1H INDOL 3 YL) 4 (7 METHOXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (5 CYCLOPROPYLETHYNYL 1 METHYL 1H INDOL 3 YL) 4 (5 FLUOROBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (5 FLUORO 1 METHYL 1H INDOL 3 YL) 4 (6 HYDROXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (5 FLUORO 1 METHYL 1H INDOL 3 YL) 4 (6 HYDROXYMETHYLBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (5 FLUORO 1 METHYL 1H INDOL 3 YL) 4 (6 METHOXYMETHYLBENZOFURAN3 YL)PYRROLE 2,5 DIONE; 3 (5 FLUORO 6 IODO 1 METHYL 1H INDOL 3 YL) 4 (7 METHOXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (5 FLUOROBENZOFURAN 3 YL) 4 (5 IODO 1 METHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 (5 FLUOROBENZOFURAN 3 YL) 4 (5 METHYL 5H [1,3]DIOXOLO[4,5 F]INDOL 7 YL)PYRROLE 2,5 DIONE; 3 (5,7 DIBROMO 1 METHYL 1H INDOL 3 YL) 4 (7 METHOXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (6 ALLYLOXYBENZOFURAN 3 YL) 4 (5 BROMO 1 METHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 (6 CHLORO 5 FLUORO 1 METHYL 1H INDOL 3 YL) 4 (6 HYDROXYMETHYLBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (6 CHLORO 5 FLUORO 1 METHYL 1H INDOL 3 YL) 4 (7 METHOXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (6 CHLORO 5 METHOXY 1 METHYL 1H INDOL 3 YL) 4 (6 CYCLOBUTYLMETHOXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (6 CHLORO 5 METHOXY 1 METHYL 1H INDOL 3 YL) 4 (6 CYCLOPROPYLMETHOXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (6 CHLORO 5 METHOXY 1 METHYL 1H INDOL 3 YL) 4 (6 METHOXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (6 HYDROXYMETHYLBENZOFURAN 3 YL) 4 (7 HYDROXYMETHYL 1 METHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 (7 METHOXYBENZOFURAN 3 YL) 4 (1 METHYL 6 TRIFLUOROMETHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 [4 (6 HYDROXYMETHYLBENZOFURAN 3 YL) 2,5 DIOXO 2,5 DIHYDRO 1H PYRROL 3 YL] 1 METHYL 1H INDOLE 5 CARBONITRILE; 3 [6 (4 CHLOROPHENYL) 5 FLUORO 1 METHYL 1H INDOL 3 YL] 4 (7 METHOXYBENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (5 IODO 1 METHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (6 CHLORO 5 FLUORO 1 METHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (6 CHLORO 5 METHOXY 1 METHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (6 IODO 5 METHOXY 1 METHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (7 HYDROXYMETHYL 1 METHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (7 METHOXYMETHYL 1 METHYL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; ANTINEOPLASTIC AGENT; BENZOFURAN 3 YL (INDOL 3 YL)MALEIMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR MODEL; PANCREAS CANCER; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOFURANS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; MALEIMIDES; MODELS, MOLECULAR; PANCREATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 64549112164     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801317h     Document Type: Article

References (26)

1. Embi, N.; Rylatt, D. B.; Cohen, P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem./FEBS 1980, 107, 519-527.
2. Woodgett, J. R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9, 2431-2438.
3. Cohen, P.; Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. ReV. Drug DiscoVery 2004, 3, 479-487.
4. Kim, L.; Kimmel, A. R. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr. Opin. Genet. DeV. 2000, 10, 508-514.
5. Hamelers, I. H.; van Schaik, R. F.; Sipkema, J.; Sussenbach, J. S.; Steenbergh, P. H. Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells. J. Biol. Chem. 2002, 277, 47645-47652.
6. Thiel, A.; Heinonen, M.; Rintahaka, J.; Hallikainen, T.; Hemmes, A.; Dixon, D. A.; Haglund, C.; Ristimèaki, A. Expression of cyclooxygenase- 2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. J. Biol. Chem. 2006, 281, 4564-4569.
7. Gregory, M. A.; Qi, Y.; Hann, S. R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 2003, 278, 51606-51612.
8. Cohen, Y.; Chetrit, A.; Cohen, Y.; Sirota, P.; Modan, B. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med. Oncol. 1998, 15, 32-36.
9. Johnson, C. D.; Puntis, M.; Davidson, N.; Todd, S.; Bryce, R. Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. Br. J. Surg. 2001, 88, 662-668.
10. Ring, D. B.; Johnson, K. W.; Henriksen, E. J.; Nuss, J. M.; Goff, D. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003, 52, 588-595.
11. Yuan, H.; Mao, J.; Li, L.; Wu, D. Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation. J. Biol. Chem. 1999, 274, 30419-30423.
12. Shakoori, A.; Ougolkov, A.; Yu, Z. W.; Zhang, B.; Modarressi, M. H.; Mai, M.; Takahashi, Y.; Minamoto, T. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem. Biophys. Res. Commun. 2005, 334, 1365-1373.
13. Mai, W.; Miyashita, K.; Shakoori, A.; Zhang, B.; Yu, Z. W.; Takahashi, Y.; Motoo, Y.; Kawakami, K.; Minamoto, T. Detection of active fraction of glycogen synthase kinase 3beta in cancer cells by nonradioisotopic in vitro kinase assay. Oncology 2006, 71, 297-305.
14. Buss, H.; Dèorrie, A.; Schmitz, M. L.; Frank, R.; Livingstone, M.; Resch, K.; Kracht, M. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J. Biol. Chem. 2004, 279, 49571-49574.
15. Ougolkov, A. V.; Fernandez-Zapico, M. E.; Savoy, D. N.; Urrutia, R. A.; Billadeau, D. D. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005, 65, 2076-2081.
16. Ougolkov, A. V.; Bone, N. D.; Fernandez-Zapico, M. E.; Kay, N. E.; Billadeau, D. D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007, 110, 735-742.
17. Meijer, L.; Flajolet, M.; Greengard, P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 2004, 25, 471-480.
18. Kozikowski, A. P.; Gaisina, I. N.; Yuan, H.; Petukhov, P. A.; Blond, S. Y.; Fedolak, A.; Caldarone, B.; McGonigle, P. Structure-based design leads to the identification of lithium mimetics that block manialike effects in rodents. Possible new GSK-3beta therapies for bipolar disorders. J. Am. Chem. Soc. 2007, 129, 8328-8332.
19. Bentley, J. M.; Adams, D. R.; Bebbington, D.; Benwell, K. R.; Bickerdike, M. J.; Davidson, J. E.; Dawson, C. E.; Dourish, C. T.; Duncton, M. A.; Gaur, S.; George, A. R.; Giles, P. R.; Hamlyn, R. J.; Kennett, G. A.; Knight, A. R.; Malcolm, C. S.; Mansell, H. L.; Misra, A.; Monck, N. J.; Pratt, R. M.; Quirk, K.; Roffey, J. R.; Vickers, S. P.; Cliffe, I. A. Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg. Med. Chem. Lett. 2004, 14, 2367-2370.
20. Bentley, J. M.; Davidson, J. E.; Duncton, M. A. J.; Giles, P. R.; Pratt, R. M. Use of a Modified Leimgruber-Batcho Reaction to Prepare 6-Chloro-5-fluoroindole. Synth. Commun. 2004, 34, 2295-2300.
21. Ponticello, G. S.; Baldwin, J. J. Useful Synthesis of 4-Substituted Indoles. J. Org. Chem. 1979, 44, 4003-4005.
22. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormèo, M.; Nilsson, Y.; Radesèater, A. C.; Jerning, E.; Markgren, P. O.; Borgegêard, T.; Nylèof, M.; Gimâenez-Cassina, A.; Hernâandez, F.; Lucas, J. J.; Dâiaz- Nido, J.; Avila, J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 2003, 278, 45937-45945.
23. Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haigh, D.; Ife, R. J.; Saunders, M.; Slingsby, B. P.; Stacey, R.; Ward, R. W. 3-Anilino-4- arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2001, 11, 635-639.
24. Vulpetti, A.; Crivori, P.; Cameron, A.; Bertrand, J.; Brasca, M. G.; D'Alessio, R.; Pevarello, P. Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis. J. Chem. Inf. Model. 2005, 45, 1282-1290.
25. Kim, K. H.; Gaisina, I.; Gallier, F.; Holzle, D.; Blond, S. Y.; Mesecar, A.; Kozikowski, A. P. Use of Molecular Modelling, Docking, and 3D-QSAR Studies for the Determination of the Binding Mode of 3-Benzofuranyl-4-indolyl-maleimides as GSK-3βInhibitors. J. Mol. Model. 2009, in press.
26. Armstrong, D. K.; Kaufmann, S. H.; Ottaviano, Y. L.; Furuya, Y.; Buckley, J. A.; Isaacs, J. T.; Davidson, N. E. Epidermal growth factormediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res. 1994, 54, 5280-5283.